InvestorsHub Logo
Followers 138
Posts 23698
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Sunday, 11/18/2018 12:11:26 PM

Sunday, November 18, 2018 12:11:26 PM

Post# of 403476
When Dr. Arthur Peter Bertolino was Vice President of Dermatology at Novartis. His team was responsible for developing Cosentyx (secukinumab.

Now, Arthur P. Bertolino, MD, PhD, MBA, as President and Chief Medical Officer at Innovation Pharmaceuticals and his team are responsible for developing Prurisol, Brilacidin and Kevetrin.

Arthur P. Bertolino, MD, PhD, MBA, as President and Chief Medical Officer

Dr. Bertolino serves as President and Chief Medical Officer at Innovation Pharmaceuticals. Dr. Bertolino is a leading pharmaceutical dermatology executive with over 15 years of domestic and global drug development and management experience. Previously, he was Vice President of Dermatology at Novartis, Vice President and Chief Medical Officer of Peplin, Inc., and Senior Director of Dermatology at Pfizer. Dr. Bertolino has authored over 50 abstracts, papers, and book chapters, and has been a regular on-air and in-print contributor to leading media companies. Dr. Bertolino received a BS (Chemistry/Biochemistry) degree from SUNY Stony Brook, an MD and PhD (Pharmacology) from The Johns Hopkins University School of Medicine, and an MBA from the University of Michigan Stephen M. Ross School of Business.

Bertolino held positions as Senior Medical Director and Senior Director of Dermatology at Pfizer (PFE).

VP, Autoimmunity/Immunology/Dermatology. Novartis. 2008 – 2013




Good luck and GOD bless,

George
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News